MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, analysis-driven pharmaceutical-high quality cannabis extraction, distillation and derivative solutions, right now announced it will provide cannabis concentrate solutions in Denmark to two new healthcare cannabis shoppers beneath two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed solutions to Denmark.
Denmark granted sufferers legal access to cannabis-primarily based medicinal solutions two years ago as aspect of a 4-year pilot plan. The plan supplies sufferers with secure solution access and national well being authorities with patient information that they can use to recognize usage and efficacy. According to facts complied by New Frontier Information and the Danish Ministry of Wellness, more than two,one hundred sufferers (mainly ladies involving the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians beneath this plan in 2019.
“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis market place for medicinal, wellness and adult use applications and these agreements represent one more step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare market place with new and revolutionary healthcare cannabis focused solutions positions us for extra development in Europe and adds to MediPharm Labs all-significant physique of information that we are leveraging to improve the design and style of our formulations for sufferers and buyers everywhere.”
Beneath the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its shoppers to commence in October 2020, pending regulatory approval by applicable well being authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured quite a few pretty eye-catching domestic and international provide agreements with higher high quality partners, now such as new shoppers in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new company wins are a clear and significant validation of our choice to create a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs developing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Excellent Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May perhaps 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, such as Denmark. The Firm entered into its initially European white-label cannabis provide agreement that very same month with Therismos Restricted.
About Denmark’s Health-related Cannabis Marketplace
Denmark launched its 4-year healthcare cannabis pilot plan on January 1st, 20181. Post-harvest Excellent Manufacturing Processes (GMP) is necessary for distribution of healthcare cannabis solutions in Denmarktwo.
Via the plan, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 regions: discomfort triggered by various sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an in depth evaluation of literature as nicely as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high quality cannabis oil and concentrates and sophisticated derivative solutions using a Excellent Manufacturing Practices certified facility with ISO regular constructed clean rooms. MediPharm Labs has invested in an professional, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 main extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its shoppers. Via its wholesale and white label platforms, they formulate, customer-test, course of action, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure
Supply: https://www.financialbuzz.com/breaking-news-medipharm-labs-enters-denmark-healthcare-cannabis-market place-secures-new-white-label-provide-shoppers/